Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common EGFR mutations

Míreanna Comhchosúla

• The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
  le: Hung, Ming-Szu, et al.
  Foilsithe: (2016)
• Comparative Analysis of Two Methods for the Detection of EGFR Mutations in Plasma Circulating Tumor DNA from Lung Adenocarcinoma Patients
  le: Hung, Ming-Szu, et al.
  Foilsithe: (2019)
• Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non‐T790M mutations after progression on first‐line EGFR‐tyrosine kinase inhibitors
  le: Jiang, Zhansheng, et al.
  Foilsithe: (2018)
• Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
  le: Liang, Sheng-Kai, et al.
  Foilsithe: (2017)
• Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study
  le: Fang, Yu-Hung, et al.
  Foilsithe: (2019)